Overview Dividends

(PODD) Insulet - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45784P1012

Insulin, Pod, CGM-Integrated, Onpro

EPS (Earnings per Share)

EPS Growth (3y CAGR): 81.70%
EPS Trend (3y Corr): 81.1%

Last SUE: 0.45σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 26.54%
Revenue Trend (3y Corr): 96.7%

Last SUE: 2.47σ
Qual. Beats: 16

Risk via 10d forecast
Volatility	72.5%
Value at Risk 5%th	109%
Relative Tail Risk	-8.76%

Reward TTM
Sharpe Ratio	0.54
Alpha	9.28

Character TTM
Hurst Exponent	0.473
Beta	0.808
Beta Downside	1.243

Drawdowns 3y
Max DD	61.31%
Mean DD	24.11%
Median DD	19.69%

Description: PODD Insulet October 16, 2025

Insulet Corporation (NASDAQ:PODD) designs, manufactures, and markets tubeless insulin-delivery systems for people with insulin-dependent diabetes, primarily in the United States but increasingly abroad. Its flagship Omnipod platform includes the Omnipod 5 automated insulin delivery (AID) system-featuring a proprietary algorithm that wirelessly links the pod to a third-party continuous glucose monitor (CGM)-and the Omnipod DASH system, which pairs a Bluetooth-enabled pod with a smartphone-style personal diabetes manager.

Beyond diabetes care, Insulet supplies specialized pods to Amgen for the Neulasta Onpro kit, a chemotherapy-support device that lowers infection risk. Sales are channeled through pharmacies and independent distributors, and the company has been operating since its 2000 incorporation in Acton, Massachusetts.

Key recent metrics: FY 2023 revenue reached $2.53 billion, up 14 % year-over-year, driven by a 23 % increase in Omnipod 5 shipments; the U.S. diabetes device market is projected to grow at a 9 % CAGR through 2028, bolstered by expanding tele-health adoption and favorable reimbursement trends for AID systems. Insulet’s market share in the tubeless pump segment rose to roughly 45 % in Q3 2024, reflecting strong brand penetration and a growing preference for patch-pump technology over traditional pumps.

For a deeper quantitative assessment, the ValueRay platform’s detailed valuation models for PODD can help you evaluate the stock’s upside potential.

PODD Stock Overview

Market Cap in USD	23,404m
Sub-Industry	Health Care Equipment
IPO / Inception	2007-05-15
Return 12m vs S&P 500	16.4%
Analyst Rating	4.43 of 5

PODD Dividends

Currently no dividends paid

PODD Growth Ratios

Metric	Value
CAGR 3y	2.15%
CAGR/Max DD Calmar Ratio	0.04
CAGR/Mean DD Pain Ratio	0.09
Current Volume	1801k
Average Volume	550.5k

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (246.2m TTM) > 0 and > 6% of Revenue (6% = 151.3m TTM)

FCFTA 0.14 (>2.0%) and ΔFCFTA 5.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 48.05% (prev 67.31%; Δ -19.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.18 (>3.0%) and CFO 533.7m > Net Income 246.2m (YES >=105%, WARN >=100%)

Net Debt (273.9m) to EBITDA (442.9m) ratio: 0.62 <= 3.0 (WARN <= 3.5)

Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (70.7m) change vs 12m ago -4.45% (target <= -2.0% for YES)

Gross Margin 71.47% (prev 69.36%; Δ 2.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 83.30% (prev 65.57%; Δ 17.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.98 (EBITDA TTM 442.9m / Interest Expense TTM 44.5m) >= 6 (WARN >= 3)

Altman Z'' 3.74

(A) 0.40 = (Total Current Assets 1.86b - Total Current Liabilities 647.7m) / Total Assets 3.03b

(B) 0.06 = Retained Earnings (Balance) 185.8m / Total Assets 3.03b

(D) 0.12 = Book Value of Equity 199.0m / Total Liabilities 1.65b

Total Rating: 3.74 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 77.33

1. Piotroski 9.0pt = 4.0

2. FCF Yield 1.78% = 0.89

3. FCF Margin 16.70% = 4.18

4. Debt/Equity 0.75 = 2.23

5. Debt/Ebitda 0.62 = 2.21

6. ROIC - WACC (= 0.80)% = 1.00

7. RoE 18.27% = 1.52

8. Rev. Trend 96.68% = 7.25

9. EPS Trend 81.12% = 4.06

What is the price of PODD shares?

As of November 21, 2025, the stock is trading at USD 312.89 with a total of 1,801,047 shares traded.
Over the past week, the price has changed by +2.83%, over one month by +5.97%, over three months by +5.77% and over the past year by +32.20%.

Is PODD a buy, sell or hold?

Insulet has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy PODD.

Strong Buy: 14
Buy: 6
Hold: 2
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the PODD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	373.6	19.4%
Analysts Target Price	373.6	19.4%
ValueRay Target Price	363.1	16.1%

PODD Fundamental Data Overview November 16, 2025

Market Cap USD = 23.40b (23.40b USD * 1.0 USD.USD)
P/E Trailing = 96.9971
P/E Forward = 55.5556
P/S = 9.2808
P/B = 16.9055
P/EG = 3.2276
Beta = 1.379
Revenue TTM = 2.52b USD
EBIT TTM = 355.1m USD
EBITDA TTM = 442.9m USD
Long Term Debt = 934.9m USD (from longTermDebt, last quarter)
Short Term Debt = 96.4m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 273.9m USD (from netDebt column, last quarter)
Enterprise Value = 23.68b USD (23.40b + Debt 1.03b - CCE 757.4m)
Interest Coverage Ratio = 7.98 (Ebit TTM 355.1m / Interest Expense TTM 44.5m)
FCF Yield = 1.78% (FCF TTM 421.2m / Enterprise Value 23.68b)
FCF Margin = 16.70% (FCF TTM 421.2m / Revenue TTM 2.52b)
Net Margin = 9.76% (Net Income TTM 246.2m / Revenue TTM 2.52b)
Gross Margin = 71.47% ((Revenue TTM 2.52b - Cost of Revenue TTM 719.6m) / Revenue TTM)
Gross Margin QoQ = 72.22% (prev 69.68%)
Tobins Q-Ratio = 7.82 (Enterprise Value 23.68b / Total Assets 3.03b)
Interest Expense / Debt = 0.68% (Interest Expense 7.00m / Debt 1.03b)
Taxrate = 28.66% (35.2m / 122.8m)
NOPAT = 253.3m (EBIT 355.1m * (1 - 28.66%))
Current Ratio = 2.87 (Total Current Assets 1.86b / Total Current Liabilities 647.7m)
Debt / Equity = 0.75 (Debt 1.03b / totalStockholderEquity, last quarter 1.38b)
Debt / EBITDA = 0.62 (Net Debt 273.9m / EBITDA 442.9m)
Debt / FCF = 0.65 (Net Debt 273.9m / FCF TTM 421.2m)
Total Stockholder Equity = 1.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.13% (Net Income 246.2m / Total Assets 3.03b)
RoE = 18.27% (Net Income TTM 246.2m / Total Stockholder Equity 1.35b)
RoCE = 15.56% (EBIT 355.1m / Capital Employed (Equity 1.35b + L.T.Debt 934.9m))
RoIC = 9.30% (NOPAT 253.3m / Invested Capital 2.72b)
WACC = 8.51% (E(23.40b)/V(24.44b) * Re(8.86%) + D(1.03b)/V(24.44b) * Rd(0.68%) * (1-Tc(0.29)))
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.57%
[DCF Debug] Terminal Value 66.85% ; FCFE base≈351.5m ; Y1≈230.8m ; Y5≈105.5m
Fair Price DCF = 25.80 (DCF Value 1.82b / Shares Outstanding 70.3m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 81.12 | EPS CAGR: 81.70% | SUE: 0.45 | # QB: 0
Revenue Correlation: 96.68 | Revenue CAGR: 26.54% | SUE: 2.47 | # QB: 16

Additional Sources for PODD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle